Seminars in Hematology
Volume 43, Issue 4 , Pages 221-229 , October 2006

Dose-Intensified Treatment of Advanced-Stage Diffuse Large B-Cell Lymphomas

  • Gerhard Held

      Affiliations

    • Innere Medizin I, Saarland University Medical School, Homburg, Germany.
    • ,
  • Joerg Schubert

      Affiliations

    • Innere Medizin I, Saarland University Medical School, Homburg, Germany.
    • ,
  • Marcel Reiser

      Affiliations

    • Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Cologne, Germany.
    • ,
  • Michael Pfreundschuh

      Affiliations

    • Innere Medizin I, Saarland University Medical School, Homburg, Germany.
    • Corresponding Author InformationAddress correspondence to Michael Pfreundschuh, MD, Klinik für Innere Medizin I, Saarland University Medical School, D-66421 Homburg (Saar), Germany.
    • ,
  • German High-Grade Non-Hodgkin-Lymphoma Study Group

References 

  1. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–994
  2. Pfreundschuh M, Truemper L, Oesterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: A randomized trial of the Mabthera International Trial (MInT) Study Group. Lancet Oncol. 2006;7:379–391
  3. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–1493
  4. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006
  5. Meyer RM, Hryniuk WM, Goodyear MD. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin’s lymphoma. J Clin Oncol. 1991;9:339–347
  6. Koppler H, Pfluger KH, Eschenbach I, Pfab R, Birkmann J, Zeller W, et al. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin’s lymphomas: Treatment results and prognostic factor analysis in a multi-centre trial. Ann Oncol. 1994;5:49–55
  7. Pfreundschuh M, Zeynalova S, Pflueger K-H, Koch P, Mergenthaler M, Bentz M, et al. Dose-escalated CHOP plus etoposide (Hi-CHOEP) is not superior to base-line CHOEP in young good-prognosis patients with aggressive lymphoma: Results of a randomized DSHNHL trial. J Clin Oncol. 2006;24:425s
  8. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–641
  9. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–633
  10. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–1545
  11. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290–1297
  12. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non- Hodgkin’s lymphoma: Final analysis of the prospective LNH87-2 protocol—A Groupe d’Etude des Lymphomes de l’Adulte study. J Clin Oncol. 2000;18:3025–3030
  13. Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non- Hodgkin’s lymphoma. N Engl J Med. 1995;332:1045–1051
  14. Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: Results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:2796–2802
  15. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordijk EM, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst. 2001;93:22–30
  16. Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol. 2002;20:4413–4419
  17. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20:2472–2479
  18. Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: An Italian multicenter randomized trial. J Clin Oncol. 2003;21:1255–1262
  19. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287–1295
  20. Betticher D, von Rohr A, Kovasovics T, Martinelli G, Cerny TL, Dyer MJS, et al. Sequential high-dose chemotherapy (SHDC) with autologous stem cell transplantation (ASCT) vs standard CHOP regimen for pts with untreated aggressive NHL (Results of the MISTRAL trial from the Swiss Group for Clinical Cancer Research (SAKK)). Ann Oncol. 2005;16:v101–v102
  21. Olivieri A, Santini G, Patti C, Chisesi T, De Souza C, Rubagotti A, et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin’s lymphoma: long-term results by the NHLCSG. Ann Oncol. 2005;16:1941–1948
  22. Vitolo U, Liberati AM, Cabras MG, Federico M, Angelucci E, Baldini L, et al. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: An “Intergruppo Italiano Linfomi” randomized trial. Haematologica. 2005;90:793–801
  23. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: Report of the jury. J Clin Oncol. 1999;17:423–429
  24. Glass B, Kloess M, Engert A, Berdel WE, Metzner B, Truemper L, et al. Mega-CHOEP repeated high dose therapy as treatment of aggressive NHL: Critical impact of time scheduling. Blood. 2002;100:776a;(abstr)
  25. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–633
  26. Pfreundschuh M, Klöss M, Schmits R, Zeynalova S, Lengfelder E, Franke A, et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2005;106:9a;(abstr)
  27. Sonneveld van Putten WL, Holte H, Biesma D, van Marwijk-Kooy M, Kramer M, Wijermans P, et al. Intensified CHOP with rituximab for intermediate or high-risk non-Hodgkin′s lymphoma: Interim analysis of a randomized phase III trial in elderly patients by the Dutch HOVON and Nordic Lymphoma groups. Blood. 2005;106:10;(abstr)
  28. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284–4289
  29. Verdonck LF, van Imhoff GW, Raemakers JMM, Verhoef G, Kramer MHH, Ossenkoppele GJ, et al. Six courses of intensified CHOP plus G-CSF compared to eight courses of standard CHOP in patients with intermediate-risk aggressive non-Hodgkin lymphoma. Blood. 2005;106:9a;(abstr)
  30. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–4126
  31. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127
  32. Glass B, Kloess M, Reiser M, Metzner B, Truemper L, Loeffler M, et al. Dose-escalated CHOP plus etoposide followed by repetitive autologous stem cell transplantation (Mega-CHOEP) with or without rituximab for primary treatment of aggressive NHL. Blood. 2005;106:430a;(abstr)
  33. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  34. Schubert J, Pfreundschuh M, Reiser M, Wenger M, Kloess M, Lengenfelder A, et al. Bi-weekly dosing preserves the efficacy of rituximab in elderly patients with poor-prognosis DLBCL: Results from the RICOVER-60 trial of the DSHNHL. J Clin Oncol. 2006;24:431s;(abstr 7536)
  35. Reiser M, Wenger M, Nickenig C, Peter N, Metzner B, Pfreundschuh M. Serum levels and pharmacokinetics of rituximab in bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial. J Clin Oncol. 2006;24:430s;(abstr)

 Supported by Deutsche Krebshilfe.

PII: S0037-1963(06)00151-X

doi: 10.1053/j.seminhematol.2006.07.003

Seminars in Hematology
Volume 43, Issue 4 , Pages 221-229 , October 2006

Article Tools

* Image Usage & Resolution